Company Filing History:
Years Active: 2016
Title: Heungnam Kim: Innovator in Cancer Treatment
Introduction
Heungnam Kim is a prominent inventor based in Pleasant Hill, CA (US). He has made significant contributions to the field of cancer research through his innovative work on human monoclonal antibodies. His research focuses on targeting glypican-3, a protein that plays a crucial role in cancer cell growth and metastasis.
Latest Patents
Heungnam Kim holds 1 patent for his invention titled "Human monoclonal antibodies specific for glypican-3 and use thereof." This patent describes the identification of human monoclonal antibodies that bind to GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies are capable of inhibiting hepatocellular carcinoma (HCC) cell growth and migration. The patent also includes compositions that consist of these antibodies, nucleic acid molecules encoding them, expression vectors, and isolated host cells that express the nucleic acids. Furthermore, it outlines methods for treating cancer and detecting it in subjects.
Career Highlights
Heungnam Kim is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work has been instrumental in advancing the understanding of cancer treatment options. His research has the potential to lead to new therapeutic strategies for patients suffering from cancer.
Collaborations
Heungnam Kim has collaborated with notable colleagues, including Mitchell Ho and Wei Gao. Their combined expertise has contributed to the success of their research initiatives.
Conclusion
Heungnam Kim's innovative work in developing human monoclonal antibodies represents a significant advancement in cancer treatment. His contributions to the field are paving the way for new therapeutic approaches that could improve patient outcomes.